AI protein design · Kraków, Poland

We design proteins that have never existed in nature

AI models can propose proteins nature never made. We build them, test them in the lab and put the results to work: with biotech partners and in our own cancer imaging and therapy programme.

Molecular illustration of a magenta binder contacting a violet target protein.
Illustrative protein interface

Why we do it

Get answers sooner for people with cancer

Cancer killed an estimated 9.8 million people worldwide in 2024. Many patients still have no treatment that targets a feature of their tumour. Developing new drugs takes years and demands substantial investment.

We call our approach agile drug discovery. AI helps us design and refine proteins faster. We plan a small imaging study to find out early whether our lead protein reaches tumours in people. Early results help us put time and funding behind the ideas that show the most promise. When it costs less to get an answer, we can test more ideas and develop new treatments faster.

IARC global cancer estimates · Study of drug development costs

Models can start with a shape, then find its sequence

Usually, a model takes a protein sequence and predicts its shape. Protein design can run the process in reverse: we search for sequences predicted to fold into a shape that grips a chosen spot on a cancer target. Then we make the proteins and test what binds. The search reaches beyond the proteins evolution has already produced.

Illustration of targeted therapy

Tumour cellHealthy cells

Services and partnerships

We design binders for biotech and pharma teams, then screen hundreds of candidates together. In the lab, we measure which ones bind. The same scale lets us turn larger scaffolds into microbinders or peptides, target flexible protein regions and bring two proteins together.

See binder discovery services

Our own drug programme

Our first programme targets a marker found across several cancers. We plan to use PET to track a tiny dose of labelled binder in people. If it reaches tumours, we can develop a therapeutic version that delivers radiation to the same target.

Explore our imaging and therapy programme